Dr. Hamburg was joined by Paul Glover of Health Canada and Guido Rasi of the European Medicines Agency at the Drug Information Association’s 48th annual meeting.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
The FDA was recently scrutinized by Congressional members who believe the agency has impeded job creation by shutting down plants with quality control problems. Dr. Hamburg stressed quality concerns, such as glass shards and metal fractures in tobacco products, could not be ignored by the FDA and other regulators.
Mr. Glover added a universal reporting mechanism could more quickly alert regulators about adverse events and promote patient safety around the world.
More Articles on Patient Safety:
Congress Passes FDA Safety and Innovation Act With Drug Shortage Provisions
Congressmen Introduce Legislation Designed to Boost Imaging Safety
AHRQ 2011 State Snapshots Spotlight Healthcare Quality, Population Health
